Testosterone monitoring for women is not about chasing a bigger number.
It is about preventing the wrong exposure.
The Global Consensus Position Statement says the only evidence-based indication for testosterone therapy in women is hypoactive sexual desire disorder. It says there are insufficient data for using testosterone for any other symptom, condition, or disease prevention. [1]
International Society for the Study of Women's Sexual Health turns that into a practical monitoring standard: identify the right patient, use doseable systemic therapy when appropriate, measure baseline total testosterone and sex hormone-binding globulin, check liver function and fasting lipids, repeat levels after starting, and keep total testosterone within the physiologic premenopausal female range. [2]
That is the authority posture for testosterone content: hypoactive sexual desire disorder first, safety range second, monitoring third, stop rule visible throughout.
What testosterone monitoring for women after menopause should include
The Global Consensus statement says hypoactive sexual desire disorder should be diagnosed after formal biopsychosocial assessment. It also says no measured androgen cutoff can distinguish women with and without sexual dysfunction. [1]
The Endocrine Society guideline reaches the same caution from another angle: it recommends against diagnosing "androgen deficiency syndrome" in otherwise healthy women because the syndrome is not well defined and androgen levels do not correlate reliably with specific symptoms. It recommends against general testosterone use for infertility, sexual dysfunction other than hypoactive sexual desire disorder, cognitive health, cardiovascular health, metabolic health, bone health, or general well-being. [4]
| Claim | Guideline-grounded answer |
|---|---|
| "My testosterone is low, so I need treatment." | A low number does not diagnose hypoactive sexual desire disorder by itself. [1] [2] |
| "Testosterone is for energy and anti-aging." | Global Consensus says the evidence-based indication is hypoactive sexual desire disorder, not broad wellness or disease prevention. [1] |
| "More testosterone should work better." | The goal is physiologic female-range exposure, not supraphysiologic dosing. [1] [2] |
| "Male TRT rules apply." | Male products may be used off label in female-appropriate dosing only when a clinician can keep levels in the female physiologic range. [1] [2] |
| "Compounded or pellets are easier." | Global Consensus and International Society for the Study of Women's Sexual Health recommend against compounded testosterone and supraphysiologic products; Global Consensus says its recommendations do not apply to pellets, injections, or supraphysiologic formulations. [1] [2] |
The wrong frame is "testosterone optimization." The right frame is a monitored hypoactive sexual desire disorder trial with defined benefit and safety boundaries.
What should be checked before starting
International Society for the Study of Women's Sexual Health recommends measuring total testosterone before therapy to exclude women with midrange to high baseline concentrations. It also recommends measuring sex hormone-binding globulin because women with high sex hormone-binding globulin are less likely to benefit. It notes high sex hormone-binding globulin may be associated with oral estrogens, thyroid replacement, and untreated hyperthyroidism. [2]
International Society for the Study of Women's Sexual Health also recommends liver function measurement and a fasting lipid profile before treatment. It says liver disease and hyperlipidemia are contraindications to testosterone therapy. [2]
| Before treatment | Why it matters |
|---|---|
| Confirm hypoactive sexual desire disorder with a biopsychosocial assessment | Testosterone is not a broad treatment for fatigue, mood, cognition, weight, or muscle. [1] [4] |
| Review modifiable contributors | Relationship strain, depression, anxiety, sleep, pain, genitourinary syndrome of menopause, medicines, alcohol, and life stress can drive low desire. [2] |
| Total testosterone | Baseline safety value; not a stand-alone hypoactive sexual desire disorder diagnostic test. [1] [2] |
| sex hormone-binding globulin | High sex hormone-binding globulin can reduce likelihood of benefit; low sex hormone-binding globulin can raise free-exposure concerns. [2] |
| Fasting lipid profile | Oral testosterone worsens lipid profile; hyperlipidemia is a contraindication in International Society for the Study of Women's Sexual Health guidance. [1] [2] |
| Liver function | Liver disease is a contraindication in International Society for the Study of Women's Sexual Health guidance. [2] |
| Product and route | The product must be doseable, adjustable, and unlikely to overshoot the female physiologic range. [1] [2] |
The safest baseline visit answers two questions: "Does this woman actually fit the hypoactive sexual desire disorder evidence category?" and "Can this product be monitored tightly enough to avoid excess?"
The monitoring schedule is specific
International Society for the Study of Women's Sexual Health recommends total testosterone testing 3 to 6 weeks after starting therapy to allow titration and ensure the patient is not applying an excessive dose. If the dose is increased, total testosterone should be repeated within 6 weeks. Once stable levels are achieved, testosterone should be monitored every 4 to 6 months to screen for overuse and androgenic consequences. [2]
The same guideline says clinicians should not treat to a target testosterone level. The point of testing is to prevent excessive dosing and make sure total testosterone does not significantly exceed the upper limit of the normal premenopausal female reference range for that laboratory. [2]
| Timing | What is being checked | What should happen if abnormal |
|---|---|---|
| Before starting | hypoactive sexual desire disorder fit, total testosterone, sex hormone-binding globulin, liver function, fasting lipids, product route, medication context. [2] | Do not start if the indication is wrong, baseline level is already high, or safety context is unfavorable. |
| 3 to 6 weeks after starting | Total testosterone and early side effects. [2] | Reduce dose if level is supraphysiologic, even without side effects. |
| Within 6 weeks after dose increase | Repeat total testosterone. [2] | Titrate down if the level exceeds the female physiologic range. |
| Every 4 to 6 months once stable | Total testosterone, clinical benefit, acne, hirsutism, scalp hair loss, voice, clitoral symptoms, mood, and overuse. [2] | Lower dose, stop, or reassess product/diagnosis if risk or no benefit emerges. |
| At 6 months without benefit | Clinically meaningful improvement. [2] | Stop rather than continue exposure without benefit. |
This schedule is a major difference between supervised testosterone care and hormone-selling.
Lipids and liver are not optional details
The 2019 systematic review and meta-analysis included 36 randomized trials and 8,480 participants. In postmenopausal women, testosterone improved sexual outcomes, including satisfactory sexual event frequency by a mean difference of 0.85 per month, sexual desire with a standardized mean difference of 0.36, and distress with a standardized mean difference of -0.27. It also increased acne and hair growth. [3]
Route mattered. The meta-analysis found oral testosterone increased low-density lipoprotein cholesterol and reduced total cholesterol, high-density lipoprotein cholesterol, and triglycerides, while nonoral routes such as transdermal patch or cream did not show the same lipid effects. The authors concluded nonoral routes are preferred because of a neutral lipid profile. [3]
The Global Consensus statement is even more direct: oral testosterone is associated with adverse lipid profiles and is not recommended. It says nonoral testosterone at physiologic doses has not shown statistically significant short-term adverse lipid effects, but also warns that trials excluded women at high cardiometabolic risk, were short, and often included concurrent estrogen therapy. [1]
| Safety issue | Practical meaning |
|---|---|
| Oral testosterone | Not recommended because of adverse lipid effects. [1] [3] |
| Nonoral physiologic dosing | Better lipid profile in short-term trial data, but long-term safety and high-risk patients remain less certain. [1] [3] |
| Hyperlipidemia | International Society for the Study of Women's Sexual Health lists this as a contraindication to testosterone therapy. [2] |
| Liver disease | International Society for the Study of Women's Sexual Health lists this as a contraindication and recommends baseline liver function testing. [2] |
| High cardiometabolic risk | Global Consensus says trial safety findings are not generalizable to a more at-risk population. [1] |
So the lipid/liver question is not a small lab detail. It is one of the main ways to keep a therapy inside the evidence boundary.
Side effects that suggest excess exposure
International Society for the Study of Women's Sexual Health says patients should be assessed for androgen excess, including acne or oily skin, hirsutism or increased facial hair, and androgenic alopecia or thinning scalp hair. It says supraphysiologic testosterone can cause acne, hirsutism, voice deepening, and androgenic alopecia. [2]
Global Consensus says physiologic systemic testosterone in postmenopausal women is associated with mild increases in acne and body or facial hair growth in some women, but not with alopecia, clitoromegaly, or voice change in the available trial data. That statement applies to physiologic dosing, not pellets, injections, compounded products, or supraphysiologic exposure. [1]
| Finding | Why it matters |
|---|---|
| New acne or oily skin | Can be an androgen-excess signal. [2] |
| New facial/body hair growth | Common enough to monitor; may signal dose excess. [2] [3] |
| Scalp hair thinning | Can indicate androgenic effect or reveal female pattern hair loss. [2] |
| Voice deepening | More concerning; supraphysiologic exposure is a risk frame. [2] |
| Clitoral symptoms | Should trigger prompt reassessment. [2] |
| Mood change or irritability | Not the primary trial endpoint, but clinically relevant for dose and risk review. |
| No desire/distress benefit | Continuing past 6 months without benefit is not guideline-aligned. [2] |
The monitoring question is not "Is the number higher?" It is "Are benefits appearing without signs of excess?"
Product choice changes monitoring risk
In the United States, International Society for the Study of Women's Sexual Health notes there is no government-approved testosterone product for hypoactive sexual desire disorder in women. It says government-approved transdermal male formulations can be used cautiously with dosing appropriate for women, but compounded products cannot be recommended because efficacy and safety data are lacking. [2]
For patient-facing copy, that should read as a dose-control and evidence boundary, not as an automatic rejection of every clinician-led compounded plan. FDA's general compounding guidance recognizes that compounding can serve patient-specific needs when an approved medication is not medically appropriate. [8] If testosterone is compounded despite the guideline caution, the rationale, pharmacy source, exact strength, concentration, dose-unit instructions, monitoring schedule, and stop rule need to be clearer than they would be for a standard label.
DailyMed's current testosterone gel 1% label, published April 2026 in a database current through June 29, 2026, is for replacement therapy in adult males with conditions associated with testosterone deficiency or absence. It says the product is not meant for use in women and includes warnings about secondary exposure, including virilization in children and changes in body hair or acne in women exposed through contact. [5]
That does not mean a clinician can never use a male gel off label for a woman. It means the label itself is not a female hypoactive sexual desire disorder protocol, and the off-label strategy must be small, measured, and monitored.
Compounded products add another problem. A study of 10 compounding pharmacies found only 50% of first batches and 30% of second batches were within plus or minus 20% of the prescribed testosterone dose; one pharmacy produced a product with essentially no testosterone. [6] The National Academies report describes compounded bioidentical hormone therapy as a public-health concern because safety and effectiveness claims often exceed the evidence. [7]
| Product or route | Monitoring concern |
|---|---|
| Doseable transdermal product | Can fit guideline care if female dosing and blood monitoring keep levels physiologic. [1] [2] |
| Oral testosterone | Not recommended because of adverse lipid effects. [1] [3] |
| Pellet | Harder to titrate down quickly; Global Consensus says recommendations do not apply to pellets that produce supraphysiologic levels. [1] |
| Injection | Peaks can overshoot; Global Consensus excludes formulations that produce supraphysiologic concentrations. [1] |
| Compounded cream/gel | Needs explicit patient-specific rationale, pharmacy verification, and dose monitoring; International Society for the Study of Women's Sexual Health/Global Consensus do not recommend routine use because of limited efficacy/safety data and dose-accuracy concerns. [1] [2] [6] [8] |
| Male gel used off label | Label is male-indicated; transfer precautions and female-range dosing discipline matter. [2] [5] |
Who this fits, and who should avoid it
A monitored testosterone trial fits best when a woman has carefully assessed hypoactive sexual desire disorder with distress, modifiable contributors have been addressed, baseline testosterone is not already midrange/high, liver function and lipids are acceptable, the product can be dose-adjusted, and follow-up can keep levels in the physiologic premenopausal female range.
It is a poor fit when the goal is energy, weight loss, muscle, mood, anti-aging, hair growth, vague "low T" optimization, or a lab number without hypoactive sexual desire disorder assessment.
| Situation | Fit judgment |
|---|---|
| Postmenopausal hypoactive sexual desire disorder with distress after biopsychosocial assessment | Evidence-supported discussion if monitoring and product choice are appropriate. [1] [2] |
| Low desire from pain, genitourinary syndrome of menopause, relationship strain, depression, medication side effects, sleep loss, or untreated illness | Address contributors first; testosterone may be the wrong first treatment. [2] |
| High baseline testosterone, supraphysiologic level on treatment, acne/hirsutism/scalp loss, or voice change | Dose reduction, product change, or stopping should be discussed. [2] |
| Hyperlipidemia or liver disease | International Society for the Study of Women's Sexual Health lists these as contraindications. [2] |
| Pellet, injection, or compounded product promoted as easier or more "natural" | Higher authority risk because guideline recommendations do not support supraphysiologic or poorly controlled exposure. [1] [2] [6] |
What to ask your clinician
- What diagnosis is testosterone treating, and how did we confirm hypoactive sexual desire disorder rather than general fatigue, mood change, relationship stress, genitourinary syndrome of menopause, medication side effects, or sleep loss?
- What were my baseline total testosterone, sex hormone-binding globulin, liver function, and fasting lipid results?
- What product and route are being used, and can the dose be reduced quickly if my level is too high?
- If the product is compounded, what patient-specific reason, pharmacy source, strength, concentration, ingredients, and dose-unit instructions make it auditable?
- When will total testosterone be checked: 3 to 6 weeks after starting, within 6 weeks after a dose increase, and every 4 to 6 months once stable?
- What lab range defines physiologic premenopausal exposure for the laboratory being used?
- What acne, facial hair, scalp hair, voice, clitoral, mood, lipid, or liver finding would trigger dose reduction or stopping?
- If desire and distress do not meaningfully improve by 6 months, will treatment stop?
Bottom line
Testosterone monitoring for women is prescription safety work, not optimization tracking.
The high-authority version is narrow: hypoactive sexual desire disorder after assessment, baseline total testosterone and sex hormone-binding globulin, baseline fasting lipids and liver function, nonoral doseable product when used, female physiologic range, repeat testing at 3 to 6 weeks, ongoing checks every 4 to 6 months, androgen side-effect review, and a stop rule by 6 months if there is no meaningful benefit.
How the assessment helps
A structured assessment can organize low-desire symptoms, prior products, baseline labs, lipid and liver context, acne or hair changes, voice or clitoral symptoms, medication interactions, and follow-up capacity so a clinician can decide whether testosterone monitoring is adequate. It is not a lab order or prescription by itself.
Related reading:
- Testosterone Therapy for Women After Menopause.
- Testosterone Blood Test for Women.
- Testosterone Pellets for Women After Menopause.
- Testosterone Side Effects in Women.
- Testosterone Gel and Cream for Women.
- dehydroepiandrosterone vs Testosterone After Menopause.
References
[1] Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429-434. doi:10.1080/13697137.2019.1637079 https://pubmed.ncbi.nlm.nih.gov/31474158/
[2] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2020.10.009 https://pubmed.ncbi.nlm.nih.gov/33814355/
[3] Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/s2213-8587(19)30189-5 https://pubmed.ncbi.nlm.nih.gov/31353194/
[4] Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-510. doi:10.1210/jc.2014-2260 https://pubmed.ncbi.nlm.nih.gov/25279570/
[5] DailyMed. Testosterone gel, 1% prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=353de205-d642-4f26-875b-b9ea4707a755
[6] Grober ED, Garbens A, Božović A, Kulasingam V, Fanipour M, Diamandis EP. Accuracy of testosterone concentrations in compounded testosterone products. J Sex Med. 2015;12(6):1381-8. doi:10.1111/jsm.12898 https://pubmed.ncbi.nlm.nih.gov/25963000/
[7] National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. https://pubmed.ncbi.nlm.nih.gov/33048485/
[8] FDA. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers